Zoledronic Acid for the treatment and prevention of primary and secondary osteoporosis.

about

Efficacy of zoledronic acid in treatment of osteoporosis in men and women-a meta-analysis.Osteoporosis - a current view of pharmacological prevention and treatment Odanacatib: an emerging novel treatment alternative for postmenopausal osteoporosis.

P2860

Q35643754-FF5B4D7B-C27F-4E4E-92E0-7E1C8F1BDF7D Q36939677-60BD5229-67AE-437B-9EB9-FACAC40F7815 Q38582108-6CB545D5-D1A2-43F7-BC0F-79AA274CB81D

P2860

Zoledronic Acid for the treatment and prevention of primary and secondary osteoporosis.

Item

http://www.wikidata.org/entity/Q36059331

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Zoledronic Acid for the treatment and prevention of primary and secondary osteoporosis.

@ast

Zoledronic Acid for the treatment and prevention of primary and secondary osteoporosis.

@en

type

Item

label

Zoledronic Acid for the treatment and prevention of primary and secondary osteoporosis.

@ast

Zoledronic Acid for the treatment and prevention of primary and secondary osteoporosis.

@en

prefLabel

Zoledronic Acid for the treatment and prevention of primary and secondary osteoporosis.

@ast

Zoledronic Acid for the treatment and prevention of primary and secondary osteoporosis.

@en

P1476

Zoledronic Acid for the treatment and prevention of primary and secondary osteoporosis.

@en

P2093

René Rizzoli

http://www.w3.org/2001/XMLSchema#string

P2860

The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies.

Current topics in pharmacological research on bone metabolism: inhibitory effects of bisphosphonates on the differentiation and activity of osteoclasts.

Osteoporosis due to cancer treatment: pathogenesis and management.

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Intravenous zoledronic acid in postmenopausal women with low bone mineral density.

Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

Zoledronic acid and clinical fractures and mortality after hip fracture.

Teriparatide or alendronate in glucocorticoid-induced osteoporosis.

Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.

Safety of intravenous and oral bisphosphonates and compliance with dosing regimens.

P304

3-16

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1759720X09352920

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2010-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230624696

http://www.w3.org/2001/XMLSchema#string

P698

22870433

http://www.w3.org/2001/XMLSchema#string

P932

3383464

http://www.w3.org/2001/XMLSchema#string

Zoledronic Acid for the treatment and prevention of primary and secondary osteoporosis.

about

P2860

P2860

Zoledronic Acid for the treatment and prevention of primary and secondary osteoporosis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932